Berbamine protects the heart from ischemia/reperfusion injury by maintaining cytosolic Ca2+ homeostasis and preventing calpain activation

CaiMei Zhang,Ling Gao,YanJun Zheng,Huangtian Yang

DOI: https://doi.org/10.1253/circj.CJ-11-1431

2012-01-01

Circulation Journal

Abstract:Background: Berbamine, a natural compound from Barberry, was reported to protect myocardium from ischemia/reperfusion (I/R) injury, but the underlying mechanisms are largely unknown. Methods and Results: Berbamine pretreatment from 10 to 100 nmol/L concentration-dependently improved postischemic myocardial function. Similar protection was confirmed in isolated cardiomyocytes characterized by the attenuation of I/R-induced intracellular free Ca2+ concentration ([Ca2+]) overloading and the depression of cell shortening and Ca2+ transients, which were partially mimicked but not augmented by calpain inhibitor calpeptin and abolished by mitochondrial ATP-sensitive potassium (mitoK(ATP)) channel inhibitor 5-hydroxydecanoate (5-HD) and phosphoinositide 3-kinase (PI3K) inhibitor wortmannin. Consistently, I/R-induced increase of calpain activity and decrease of sarcoplasmic reticulum Ca2+. ATPase (SERCA2) activity; and protein expression of SERCA2a, desmin, calpastatin and Akt was significantly attenuated by berbamine. In addition, I/R-decreased Akt protein was reversed by calpeptin. Moreover, berbamine further increased I/R-enhanced phosphorylation of Akt and glycogen synthase kinase-3 beta (GSK3 beta). These protections were abolished by wortmannin. Furthermore, berbamine significantly attenuated I/R-induced lactate dehydrogenase release, infarct size and contractile dysfunction, and such cardioprotective actions were abolished by wortmannin and 5-HD or mimicked by glycogen synthase kinase-3 beta (GSK3 beta) inhibitor SB216763 but without additive effect. Conclusions: These findings suggest that berbamine confers cardioprotection against I/R injury by attenuating [Ca2+](i) overloading and preventing calpain activation through the activation of the PI3K-Akt-GSK3 beta pathway and, subsequently, opening of the mitoK(ATP) channel. (Circ J 2012; 76: 1993-2002)